ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

BMS And Allergan Link For Pain Drug

by Michael McCoy
March 8, 2010 | APPEARED IN VOLUME 88, ISSUE 10

Bristol-Myers Squibb and Allergan have formed an agreement to develop and commercialize Allergan’s AGN-209323, an oral drug in clinical development for neuropathic pain. Under the deal, Allergan grants BMS worldwide rights to the “Phase II ready” compound, except for use in products formulated for local delivery to the eye. BMS will pay Allergan $40 million up front and could owe the firm up to $373 million in milestone payments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment